Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pediococcus acidilactici CE51
- Development stage
- Preclinical
- Lead developer
- Centro Universitário de Araraquara
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Pediococcus acidilactici CE51 is a specific probiotic strain of lactic acid bacteria investigated for its potential therapeutic effects in inflammatory bowel diseases, particularly ulcerative colitis. In preclinical murine models of dextran sodium sulfate (DSS)-induced colitis, the administration of this strain (often via a food matrix like orange juice) has demonstrated the ability to attenuate intestinal inflammation, reduce splenomegaly, and positively modulate the gut microbiota composition. Its mechanism involves maintaining the balance of the phylum Firmicutes/Bacteroidetes and promoting the growth of beneficial bacteria such as Lactobacillus helveticus. While it does not significantly alter systemic markers like serum TNF-α or C-reactive protein in some studies, its local effects on the intestinal mucosa suggest a protective role against colitis-induced damage.
- Other names
- P. acidilactici CE51
Beyond the preview
Go deeper on Pediococcus acidilactici CE51.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pediococcus acidilactici CE51.